6:12 PM
 | 
Feb 13, 2013
 |  BC Extra  |  Clinical News

Ablynx jumps on final Phase II RA data

Ablynx N.V. (Euronext:ABLX) jumped EUR 0.81 (12%) to EUR 7.70 on Wednesday after reporting final 24-week data from the Phase II portion of a Phase I/II trial evaluating IV ALX-0061 to treat moderate to severe active rheumatoid arthritis. In 24 evaluable patients on a stable...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >